BRPI0413215A - peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta) - Google Patents
peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta)Info
- Publication number
- BRPI0413215A BRPI0413215A BRPI0413215-7A BRPI0413215A BRPI0413215A BR PI0413215 A BRPI0413215 A BR PI0413215A BR PI0413215 A BRPI0413215 A BR PI0413215A BR PI0413215 A BRPI0413215 A BR PI0413215A
- Authority
- BR
- Brazil
- Prior art keywords
- tgf
- beta
- growth factor
- transforming growth
- binding
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000009618 Transforming Growth Factors Human genes 0.000 abstract 1
- 108010009583 Transforming Growth Factors Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000009543 pathological alteration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
PEPTìDEOS COM A CAPACIDADE PARA LIGAREM-SE A FATOR DE CRESCIMENTO TRANSFORMADOR BETA 1 (TGF-BETA 1) Os peptídeos descritos possuem a capacidade para ligarem-se a Fator de Crescimento Transformador TGF-beta 1 (TGF-beta1), e são potenciais inibidores da atividades biológica de TGF-beta 1 através da ligação direta a esta citoquina. Estes peptídeos podem ser usados no tratamento de doenças ou alterações patológicas baseadas na expressão TGF-beta 1 desregulada ou excessiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200302020A ES2304069B1 (es) | 2003-08-22 | 2003-08-22 | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
| PCT/ES2004/000320 WO2005019244A1 (es) | 2003-08-22 | 2004-07-05 | Péptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-beta1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413215A true BRPI0413215A (pt) | 2007-06-19 |
Family
ID=34203356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413215-7A BRPI0413215A (pt) | 2003-08-22 | 2004-07-05 | peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7666841B2 (pt) |
| EP (1) | EP1669367B1 (pt) |
| JP (1) | JP4902352B2 (pt) |
| CN (1) | CN100424093C (pt) |
| AT (1) | ATE479702T1 (pt) |
| AU (2) | AU2004266856A1 (pt) |
| BR (1) | BRPI0413215A (pt) |
| CA (1) | CA2535807A1 (pt) |
| CY (1) | CY1110885T1 (pt) |
| DE (1) | DE602004028949D1 (pt) |
| DK (1) | DK1669367T3 (pt) |
| ES (2) | ES2304069B1 (pt) |
| HR (1) | HRP20100637T1 (pt) |
| PL (1) | PL1669367T3 (pt) |
| PT (1) | PT1669367E (pt) |
| RU (2) | RU2333917C2 (pt) |
| SI (1) | SI1669367T1 (pt) |
| WO (1) | WO2005019244A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158589B2 (en) * | 2003-08-22 | 2012-04-17 | Proyecto Biomedicine Cima, S.L. | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
| CN101340927A (zh) * | 2005-10-24 | 2009-01-07 | 西玛生物医学信息公司 | TGF-β1抑制性多肽在制备免疫反应调节剂上的用途 |
| RU2420307C2 (ru) * | 2005-10-24 | 2011-06-10 | Проекто Де Биомедисина Сима, С.Л. | ПРИМЕНЕНИЕ ИНГИБИРУЮЩИХ TGF-бета1 ПЕПТИДОВ ДЛЯ ПРИГОТОВЛЕНИЯ МОДУЛИРУЮЩЕГО ИММУННЫЙ ОТВЕТ АГЕНТА |
| ES2327088B1 (es) * | 2007-08-20 | 2010-07-26 | Proyecto De Biomedicina Cima S.L. | Combinaciones terapeuticas para el tratamiento de las metastasis. |
| ES2337973B8 (es) | 2008-05-16 | 2011-07-21 | Proyecto De Biomedicina Cima, S.L. | Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad. |
| ES2330826B1 (es) | 2008-06-04 | 2010-07-26 | Proyecto De Biomedicina Cima, S.L. | Sistema para empaquetamiento de adenovirus de alta capacidad. |
| WO2009150284A2 (es) | 2008-06-13 | 2009-12-17 | Proyecto De Biomedicina Cima, S.L. | Conjugados de apo-a para la administración de compuestos biológicamente activos |
| CA2750559A1 (en) * | 2009-02-05 | 2010-08-12 | Digna Biotech, S.L. | Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides |
| EP2497830A1 (en) | 2009-11-05 | 2012-09-12 | Proyecto de Biomedicina Cima, S.L. | Regulated expression systems |
| RU2413769C1 (ru) * | 2009-12-24 | 2011-03-10 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pET-32a, КОДИРУЮЩАЯ ГЕН ЛИГАНД-СВЯЗЫВАЮЩЕГО ДОМЕНА РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА-β ЧЕЛОВЕКА (TβRII), ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ СЛИТНОГО БЕЛКА ТИОРЕДОКСИН/TβRII И СПОСОБ РЕНАТУРАЦИИ И ОЧИСТКИ ЦЕЛЕВОГО БЕЛКА TβRII |
| WO2012001196A2 (es) | 2010-06-28 | 2012-01-05 | Proyecto De Biomedicina Cima, S.L. | Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos |
| KR101029705B1 (ko) * | 2010-06-30 | 2011-04-18 | (주)엔솔테크 | 신규 펩타이드 및 그 용도 |
| EP2407534A1 (en) | 2010-07-14 | 2012-01-18 | Neo Virnatech, S.L. | Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions |
| EP2785861B1 (en) | 2011-11-28 | 2020-01-15 | Institució Catalana de Recerca i Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| WO2013113755A1 (en) | 2012-01-30 | 2013-08-08 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway |
| US20150289795A1 (en) | 2012-11-12 | 2015-10-15 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| US20140170158A1 (en) * | 2012-12-17 | 2014-06-19 | The Johns Hopkins University | Compositions and methods for treating or preventing lung diseases |
| ES2523016B1 (es) | 2013-05-20 | 2015-09-09 | 3P Biopharmaceuticals | Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes |
| JP6730701B2 (ja) | 2013-11-14 | 2020-07-29 | 学校法人同志社 | 細胞増殖促進または細胞障害抑制による角膜内皮治療薬 |
| EP2878674A1 (en) | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| WO2015101666A1 (en) | 2014-01-03 | 2015-07-09 | Fundación Biofísica Bizkaia | VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF |
| US20170121685A1 (en) | 2015-11-02 | 2017-05-04 | Tigenix S.A.U. | Mesenchymal stem cell-derived exosomes and their uses |
| CA3008113C (en) | 2015-12-24 | 2024-10-29 | The Doshisha | A MEDICINE FOR THE TREATMENT OR PREVENTION OF A DISORDER CAUSED BY TGF-β SIGNALS AND ITS APPLICATION |
| GB201707561D0 (en) * | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| US11576914B2 (en) | 2017-07-26 | 2023-02-14 | The Doshisha | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08151396A (ja) * | 1994-11-28 | 1996-06-11 | Teijin Ltd | Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤 |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6509318B1 (en) * | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
| EA200500576A1 (ru) * | 2002-11-01 | 2006-02-24 | Бойз Таун Нэшнл Рисерч Хоспитал | ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯ |
-
2003
- 2003-08-22 ES ES200302020A patent/ES2304069B1/es not_active Expired - Fee Related
-
2004
- 2004-07-05 PT PT04742049T patent/PT1669367E/pt unknown
- 2004-07-05 AT AT04742049T patent/ATE479702T1/de active
- 2004-07-05 AU AU2004266856A patent/AU2004266856A1/en not_active Abandoned
- 2004-07-05 DE DE602004028949T patent/DE602004028949D1/de not_active Expired - Lifetime
- 2004-07-05 WO PCT/ES2004/000320 patent/WO2005019244A1/es not_active Ceased
- 2004-07-05 EP EP04742049A patent/EP1669367B1/en not_active Expired - Lifetime
- 2004-07-05 US US10/569,012 patent/US7666841B2/en not_active Expired - Fee Related
- 2004-07-05 CN CNB200480024201XA patent/CN100424093C/zh not_active Expired - Fee Related
- 2004-07-05 BR BRPI0413215-7A patent/BRPI0413215A/pt not_active IP Right Cessation
- 2004-07-05 DK DK04742049.2T patent/DK1669367T3/da active
- 2004-07-05 PL PL04742049T patent/PL1669367T3/pl unknown
- 2004-07-05 SI SI200431516T patent/SI1669367T1/sl unknown
- 2004-07-05 CA CA002535807A patent/CA2535807A1/en not_active Abandoned
- 2004-07-05 ES ES04742049T patent/ES2351865T3/es not_active Expired - Lifetime
- 2004-07-05 JP JP2006524375A patent/JP4902352B2/ja not_active Expired - Fee Related
- 2004-07-05 HR HR20100637T patent/HRP20100637T1/hr unknown
- 2004-07-05 RU RU2006109011/13A patent/RU2333917C2/ru not_active IP Right Cessation
-
2008
- 2008-04-21 RU RU2008115678/10A patent/RU2455358C2/ru not_active IP Right Cessation
-
2010
- 2010-08-20 AU AU2010212466A patent/AU2010212466B2/en not_active Ceased
- 2010-11-12 CY CY20101101024T patent/CY1110885T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004266856A1 (en) | 2005-03-03 |
| PL1669367T3 (pl) | 2011-02-28 |
| PT1669367E (pt) | 2010-12-07 |
| DE602004028949D1 (en) | 2010-10-14 |
| RU2333917C2 (ru) | 2008-09-20 |
| EP1669367B1 (en) | 2010-09-01 |
| CA2535807A1 (en) | 2005-03-03 |
| ATE479702T1 (de) | 2010-09-15 |
| US7666841B2 (en) | 2010-02-23 |
| US20070142275A1 (en) | 2007-06-21 |
| ES2351865T3 (es) | 2011-02-11 |
| DK1669367T3 (da) | 2010-11-08 |
| HRP20100637T1 (hr) | 2010-12-31 |
| JP2007525204A (ja) | 2007-09-06 |
| JP4902352B2 (ja) | 2012-03-21 |
| WO2005019244A1 (es) | 2005-03-03 |
| EP1669367A1 (en) | 2006-06-14 |
| AU2010212466B2 (en) | 2012-07-19 |
| RU2008115678A (ru) | 2009-10-27 |
| CY1110885T1 (el) | 2015-06-10 |
| RU2006109011A (ru) | 2006-07-27 |
| ES2304069B1 (es) | 2009-08-12 |
| ES2304069A1 (es) | 2008-09-01 |
| CN1839149A (zh) | 2006-09-27 |
| RU2455358C2 (ru) | 2012-07-10 |
| SI1669367T1 (sl) | 2010-11-30 |
| AU2010212466A1 (en) | 2010-09-09 |
| CN100424093C (zh) | 2008-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413215A (pt) | peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta) | |
| BR0113420A (pt) | Anticorpos para il-1beta humano | |
| DE602004022061D1 (de) | Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen | |
| DE60327745D1 (de) | Verwendung von adapalen zur behandlung dermatologischer erkrankungen | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE536188T1 (de) | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon | |
| CY1111518T1 (el) | Tgf βητα 1 ειδικα αντισωματα | |
| EP2628751A3 (en) | Binding members for interleukin-6 and use thereof | |
| EP1755661A4 (en) | USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS | |
| ATE540949T1 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| TNSN07036A1 (en) | Human monoclonal antibodies against human il-4 | |
| ATE326842T1 (de) | Zusammensetzung zur saatgutbehandlung | |
| DE602005021970D1 (de) | Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen | |
| EP1660682A4 (en) | ANTISENSE MODULATION OF P38 MITOGEN-ACTIVATED PROTEIN KINASE EXPRESSION | |
| ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| EA200601884A1 (ru) | Бета-карболины, применяемые для лечения воспалительных заболеваний | |
| ATE527377T1 (de) | Erstellung von genexpressionprofilen aus ffpe- proben | |
| ATE475315T1 (de) | Mittel zur biologischen bekämpfung pilzlicher pflanzenkrankheiten | |
| EA200600561A1 (ru) | Фармацевтический препарат для лечения шока | |
| DE602004023199D1 (de) | Fluoreszenzprotein und pigmentprotein | |
| ATE543833T1 (de) | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen | |
| DE60107888D1 (de) | Beta-Interferon zur Behandlung von Immunerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2261 DE 06/05/2014. |